Evidence map›Paper›PMID 38083880›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

3-aryl-4-(3,4,5-trimethoxyphenyl)pyridines inhibit tubulin polymerisation and act as anticancer agents.

Chao Wang, Yujing Zhang, Shanbo Yang, Lingyu Shi, Yutao Xiu, Yudong Wu, Hongfei Jiang

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Novel 6-aryl-1-(3,4,5-trimethoxyphenyl)-1Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  2. Conformationally constrained 6‑aryl‑1‑(3,4,5‑trimethoxyphenyl)-1Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  3. Article
  4. Design, synthesis,Frontiers in chemistry · 2025
    Article
  5. Design, synthesis, and bioevaluation of 1Journal of enzyme inhibition and medicinal chemistry · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chao WangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Yujing ZhangThe Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, China.
Shanbo YangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Lingyu ShiCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Yutao XiuCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Yudong WuCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Hongfei JiangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Affiliated Hospital of Qingdao University · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of

Indexed as

Antineoplastic AgentsTubulinCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHeLa CellsHumansMolecular Docking SimulationMolecular StructurePyridinesStructure-Activity RelationshipTubulin ModulatorsAntineoplastic AgentsPyridinesTubulinTubulin Modulatorsantiproliferative activityCombretastatin A-4molecular dockingpyridinetubulin

Identifiers

PMID38083880
PMCPMC11721755
OpenAlexW4389619340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.